Injectable dopamine-modified poly(alpha,beta-aspartic
acid) nanocomposite hydrogel as bioadhesive drug delivery system
Gong, C (Gong, Chu)[ 1 ] ; Lu, CC (Lu, Caicai)[ 1,2 ] ; Li, BQ (Li, Bingqiang)[ 1 ] ; Shan, M (Shan, Meng)[ 1 ] ; Wu, GL (Wu, Guolin)[ 1 ]
JOURNAL OF
BIOMEDICAL MATERIALS RESEARCH PART A, 2017, 105(4): 1000-1008
DOI: 10.1002/jbm.a.35931
WOS:000395008300005
Abstract:
Hydrogel systems based on cross-linked polymeric
materials with adhesive properties in wet environments have been considered as
promising candidates for tissue adhesives. The 3,4-dihydroxyphenylalanine
(DOPA) is believed to be responsible for the water-resistant adhesive
characteristics of mussel adhesive proteins. Under the inspiration of DOPA
containing adhesive proteins, a dopamine-modified poly(alpha,beta-aspartic
acid) derivative (PDAEA) was successfully synthesized by successive
ring-opening reactions of polysuccinimide (PSI) with dopamine and ethanolamine,
and an injectable bioadhesive hydrogel was prepared via simply mixing PDAEA and
FeCl3 solutions. The formation mechanism of the hydrogel was investigated by
ultraviolet-visible (UV-vis) spectroscopic, Fourier transformation infrared
(FT-IR) spectroscopic, visual colorimetric measurements and EDTA immersion
methods. The study demonstrated that the PDAEA-Fe3+ hydrogel is a dual
cross-linking system composed of covalent and coordination crosslinks. The PDAEA-Fe3+
hydrogel is suitable to serve as a bioadhesive agent according to the
rheological behaviors and the observed significant shear adhesive strength. The
slow and sustained release of the model drug curcumin from the hydrogel in
vitro demonstrated the hydrogel could also be potentially used for drug
delivery. Moreover, the cytotoxicity tests in vitro suggested the prepared
polymer and hydrogel possessed excellent cytocompatibility. All the results
indicated that the dopamine modified poly(alpha,beta-aspartic acid) derivative
based hydrogel was a promising candidate for bioadhesive drug delivery system.
(C) 2017 Wiley Periodicals, Inc.
